# Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria

Study · id `cardio:ct-nct01500590` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01500590](<https://clinicaltrials.gov/study/NCT01500590>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01500590

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 1400 participants.

## Technical summary

Registry record NCT01500590. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1400 participants (enrolled count; ClinicalTrials.gov record NCT01500590, source copy `cardio:ctgov-nct01500590-2016-09-05`, retrieved 2026-10-26)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT01500590, source copy `cardio:ctgov-nct01500590-2016-09-05`, retrieved 2026-10-26)
- Primary completion: 2018-08 (anticipated) (ClinicalTrials.gov record NCT01500590, source copy `cardio:ctgov-nct01500590-2016-09-05`, retrieved 2026-10-26)
- Completion: 2019-08 (anticipated) (ClinicalTrials.gov record NCT01500590, source copy `cardio:ctgov-nct01500590-2016-09-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01500590, source copy `cardio:ctgov-nct01500590-2016-09-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01500590-2016-09-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
- Acronym: eGFR
- Condition: Diabetes
- Condition: Hypertensive Disease
- Intervention (Drug): Renin-angiotensin system blockers
- Intervention (Drug): non-renin angiotensin system blockers
- Lead sponsor: Hospital Authority, Hong Kong
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 5b2d815a41286f5cd47b6fd8e1d4792454613333073992e56b0b764ebc6466c5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
